Pharmacogenetic approach for cancer treatment - Tailored medicine in practice
Pharmacogenetic approach for cancer treatment - Tailored medicine in practice
复制标题
DOI：
10.1196/annals.1377.020
复制
发表时间：
2006-01-01
期刊：
影响因子：
--
通讯作者：
Shimokata, Kaoru
中科院分区：
文献类型：
--
作者：
Hasegawa, Yoshinori;Ando, Yuichi;Shimokata, Kaoru
本文重点介绍尿苷二磷酸葡萄糖醛酸转移酶（UGT）1A 1基因多态性与伊立替康毒性之间的药物遗传学关联。越来越多的证据支持伊立替康治疗前测定UGT 1A 1多态性对于预测和避免相关毒性具有临床意义和重要性的观点。基于这些背景，2005年在美国更新了伊立替康标签，以提供药物遗传学信息，当与其他药物或单药联合给药时，对于已知UGT 1A 1 *28等位基因纯合子的患者，应考虑降低伊立替康剂量。伊立替康/UGT 1A 1问题和分子诊断检测的发展现在将转化为临床实践。
This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT)1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is clinically useful and important for predicting and avoiding related toxicities. On the basis of these backgrounds, the irinotecan label was updated in 2005 in the United States to provide pharmacogenetic information, and a dose reduction of irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele when administered in combination with other agents or a single agent. The irinotecan/UGT1A1 issue and the development of molecular diagnostic testing are now to be translated into clinical practice.